EbsArgent™

About Thioredoxin Systems

Thioredoxin Systems is a preclinical-stage biotech company tackling the global crisis of antimicrobial resistance through a novel mechanism of action. Its lead candidate, EbsArgent™, is a combination of ebselen and silver ions designed to disable the essential bacterial thioredoxin reductase system, showing efficacy against all WHO-classified critical priority pathogens. The company is initially focused on developing EbsArgent for complicated urinary tract infections, a significant unmet medical need with high hospitalization rates. Founded on the groundbreaking redox research of Professor Arne Holmgren, the company is privately held and advancing its program through preclinical development.

Therapeutic Areas